Nanoparticle-Mediated Delivery of Therapeutics for Blood Cancer Treatment: A Review of Recent Developments
نویسندگان
1 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al Ahliyya Amman University, Amman 19328, Jordan
2 Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India
3 Department of Pharmacy Practice, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India
4 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al Ahliyya Amman University, Amman 19328, Jordan
5 Department of quality assurance, R.C. Patel Institute of Pharmacy, shirpur 425405, Maharashtra, India
6 Faculty of Pharmacy, Mutah University, 61710 Al Karak, Jordan
7 Department of Pharmaceutical Sciences, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia
8 Department of Pharmaceutical Quality Assurance, Krishna Institute of Pharmacy Krishna Vishwa Vidyapeeth Karad Maharashtra 415539, India
9 Department of Pharmaceutical Chemistry, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India
doi
10.48309/jcr.2025.511889.1423چکیده
Blood cancers, such as leukemia, lymphoma, and multiple myeloma (MM), present considerable treatment challenges owing to issues such as drug resistance, systemic toxicity, and the limited bioavailability of traditional therapies. Nanoparticle-mediated drug delivery offers a promising solution by enabling targeted and controlled drug release. This review summarizes the recent progress in nanoparticle-based approaches for treating blood cancers, highlighting various types of nanoparticles, including lipid-based, polymeric, metallic, carbon-based, and exosome-derived carriers. Each nanoparticle class has distinct benefits, such as improved drug stability, extended circulation time, and enhanced accumulation of drugs in tumours. In addition, we examined the advantages of nanoparticle-mediated therapies, including better bioavailability, decreased systemic toxicity, and increased treatment effectiveness. However, challenges related to nanoparticle stability, toxicity, and clinical application still pose significant obstacles. This review concludes by exploring future directions in nanomedicine, such as innovative nanoparticle functionalization, combination therapies, and personalized treatment strategies. The insights provided in this review aim to inform the ongoing research and development of nanoparticle-based therapies for blood cancers, ultimately enhancing patient outcomes.
